About Conduit

Formed in 2019, Conduit is a clinical stage specialty biopharmaceutical company, addressing unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. The development pipeline includes a glucokinase activator in a number of Phase II ready autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor and renal transplant. Conduit’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility. Following successful clinical trials, Conduit licences these assets to large pharma, typically for milestone payments and retains a royalty income stream for the life of the asset patent and will use its royalty income stream to develop its portfolio of programmes, balancing forward income stream sales and debt or equity.

In partnership with St. George Street Capital, a UK registered charity, Conduit completed the successful ARCADIA Clinical Trial to assess the safety and efficacy AZD1656 in 150 patients with either Type 1 or Type 2 diabetes who have been hospitalised with COVID-19. Click here to view the publication in Lancet eClinicalMedicine of the successful ARCADIA Phase II Clinical Trial